MAIA Biotechnology, Inc.
  • About
    • About Us
    • Management
    • Board of Directors
    • Advisors
    • Careers
  • Programs
    • Pipeline
    • THIO Program
    • Second-Generation Programs
    • Publications
  • Partners
  • Investors
  • Contact
  • Menu Menu
  • Twitter
  • LinkedIn

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Press Releases
    • IR Calendar
    • Email Alerts
  • Company Info
    • Management Team
    • Analyst Coverage
    • Presentations
    • Contacts
    • FAQ
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Board of Directors
    • Board Committees
    • Governance Documents
  • News & Events

  • Press Releases
  • IR Calendar
  • Email Alerts
Mar 13, 2023 10:04am EDT

MAIA Biotechnology Announces No Exposure to Silicon Valley Bank

Mar 07, 2023 8:00am EST

MAIA Biotechnology Doses First Patients in Europe in Ongoing Phase 2 Trial (THIO-101) Evaluating THIO for Non-Small Cell Lung Cancer Treatment

Feb 13, 2023 8:00am EST

ADDING MULTIMEDIA: MAIA Biotechnology’s Telomere-targeting Agent THIO, in Combination With Checkpoint Inhibitor Immune Therapies Atezolizumab (anti-PD-L1) or Pembrolizumab (anti-PD-1), Demonstrated Significantly Greater Tumor Inhibition

Jan 17, 2023 10:00am EST

Sidoti's January Micro-Cap Conference

Jan 17, 2023 8:00am EST

MAIA Biotechnology Advances New Telomere-Targeting Molecule Program

Jan 05, 2023 8:00am EST

MAIA Biotechnology to Participate in Four Upcoming Investor Conferences

Dec 20, 2022 8:00am EST

MAIA Biotechnology Holds Successful Pre-IND Meeting with FDA for Planned US Expansion of THIO-101 Phase 2 Trial for Non-Small Cell Lung Cancer

Dec 13, 2022 8:00am EST

MAIA Biotechnology Expands Phase 2 THIO-101 Trial to Europe

Nov 22, 2022 8:00am EST

MAIA Biotechnology Announces Establishment of Rule 10b5-1 Trading Plan

Nov 15, 2022 8:00am EST

MAIA Biotechnology Presents Preclinical Data at SITC Annual Meeting Validating Efficacy of THIO in Treating Hepatocellular Carcinoma

  • 1
  • 2
  • 3
  • 4
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
© Copyright 2023 - MAIA Biotechnology, Inc.     312.416.8592     |     info@maiabiotech.com     |     Terms of Use    |     Privacy Policy    |     Cookies Policy